The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.
The company posted $1.3 million in revenues with OVA1 test sales up 82 percent to 3,602 and revenue per test down 8 percent to $345.
The firm, which went public in September said that full-year 2019 revenues are expected to be between $40 million and $431 million.
The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.
HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.
Due to a ransom cyberattack on its information technology systems, the firm reported full revenue but only preliminary earnings estimates.
The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.
The company said revenues declined primarily as a result of adjustments in accounts receivable, payor mix, and the timing of test kit collections.
The company posted higher total sales for the first half of its fiscal year 2020 on sales growth in both in Japan and internationally.
The liquid biopsy firm reported revenues of $60.8 million for the quarter, easily surpassing the consensus Wall Street estimate of $45.4 million.